Abstract: The invention relates to benzothiadiazole compounds of formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R1, R2, A, B, C, W, Z and n are defined as set forth in the specification. The compounds of the invention have affinity for the nociceptin receptor. The invention is also directed to the use of compounds of Formula (I) to treat a disorder responsive to modulation of the nociceptin receptor. Compounds of the present invention are especially useful for treating pain.
Type:
Grant
Filed:
March 1, 2005
Date of Patent:
July 21, 2009
Assignee:
Purdue Pharma, L.P.
Inventors:
R. Richard Goehring, Zhengming Chen, John Whitehead, Parviz Gharagozloo, Sam Victory, Donald Kyle
Abstract: The present invention provides a device, preferably a collar or ear tag, capable of the controlled, sustained release of an effective amount of an active ingredient that can protect an animal against arthropod pests, comprising a reservoir containing a novel gel formulation comprising a fatty acid, an organic solvent which is a linear aliphatic ester, a silicone-based fluid, or a combination thereof, and an active ingredient that can protect the animal against one or more arthropod pests.
Abstract: This invention relates to immunogenic compositions capable of potentiality growth hormone activity, comprising an immunologically effective amount of a composite peptide comprising at least two non-contiguous somatotropin epitope amino acid sequences, wherein said composite peptide is substantially free of receptor binding domain sequences; and an immunologically acceptable excipient. The invention further relates to methods of using an immunogenic composition of the invention to potentiate the action of growth hormone in pigs.
Type:
Grant
Filed:
March 26, 1999
Date of Patent:
December 11, 2001
Assignee:
Pfizer Inc
Inventors:
Hector Wasunna Alila, Michael Thomas Clark, Elaine Verne Jones, Timothy Joe Miller, Shawn Patrick O'Brien, Ganesh Madhusudan Sathe
Abstract: The present invention provides polynucleotide molecules encoding portions of the S protein from feline infectious peritonitis virus (FIPV). The present invention further provides polynucleotide molecules encoding the entire S protein or portions thereof from feline enteric coronavirus (FECV). The polynucleotide molecules of the present invention are useful as diagnostic reagents.
Type:
Grant
Filed:
February 22, 1995
Date of Patent:
August 28, 2001
Assignee:
Pfizer Inc
Inventors:
Timothy J. Miller, Albert Paul Reed, Sharon R. Klepfer, Nancy E. Pfeiffer, Brian T. Suiter, Elaine V. Jones
Abstract: A microencapsulated subunit component from bovine herpes virus-1 (BHV-1) is disclosed. Vaccines, kits, and methods for using the same to vaccinate a member of a bovine species are also disclosed.
Type:
Grant
Filed:
April 21, 1998
Date of Patent:
August 7, 2001
Assignee:
Pfizer Inc.
Inventors:
Tully J. Speaker, H. Fred Clark, Charlotte A. Moser, Paul A. Offit, Manuel Campos, Patrick J. Frenchick
Abstract: A method of treating diseases caused by sebaceous gland disorders, in humans and animals, which comprises administering to said humans and animals a composition comprising a sebaceous gland secretion inhibiting amount of an active compound comprising an acyl coA cholesterol acyl transferase (ACAT) inhibitor or prodrug therefor.
A composition for use in treating diseases caused by sebaceous gland disorders such as acne in humans and animals which comprises a sebaceous gland secretion inhibiting amount of an acyl coA cholesterol acyl tanferase (ACAT) inhibitor or prodrug therefor and, optionally, a pharmaceutically acceptable carrier.
Abstract: The present invention relates to an improved method for synthesizing nucleosides with a low &agr;:&bgr; anomeric ratio. The method comprises coupling a protected furanosyl halide and an appropriately protected heterocycle in the presence of a nucleophilic polar solvent and a strong base.
Abstract: The present invention relates to polynucleotide molecules comprising nucleotide sequences encoding an aveC gene product, which polynucleotide molecules can be used to alter the ratio or amount of class 2:1 avermectins produced in fermentation cultures of S. avermitilis. The present invention further relates to vectors, host cells, and mutant strains of S. avermitilis in which the aveC gene has been inactivated, or mutated so as to change the ratio or amount of class 2:1 avermectins produced.
Type:
Grant
Filed:
August 12, 1999
Date of Patent:
June 19, 2001
Assignee:
Pfizer Inc
Inventors:
Kim J. Stutzman-Engwall, Hamish McArthur, Yoshihiro Katoh
Abstract: This invention relates to a novel improved process for preparation of N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenylidene]methanamine from 4-(3,4-dichloro-phenyl)-3,4-dihydro-1(2H)-naphthalenone and monomethylamine.
Type:
Grant
Filed:
September 2, 1999
Date of Patent:
May 15, 2001
Assignee:
Pfizer Inc
Inventors:
Juan Carlos Colberg, David Michael Pfisterer, Geraldine Patricia Taber
Abstract: The present invention is directed to compositions and methods for producing avermectins, and is primarily in the field of animal health. The present invention relates to the identification and characterization of two novel genes, herein referred to as the aveR1 and aveR2 genes, that are involved in regulating avermectin polyketide synthase (PKS) expression and avermectin biosynthesis in Streptomyces avermitilis. The present invention is based on the discovery that inactivation of these genes results in an increase in the amount of avermectin produced by S. avermitilis.
Type:
Grant
Filed:
September 7, 1999
Date of Patent:
March 6, 2001
Assignee:
Pfizer Inc.
Inventors:
Kim J. Stutzman-Engwall, Brenda S. Price
Abstract: This invention relates to the isochroman compound of formula (I)
and its pharmaceutically acceptable salts, which are useful as an amyloid aggregation inhibitor and for treating Alzheimer's disease. This invention also relates to processes for producing the isochroman compound, which comprises cultivating Penicillium simplicissimum FERM BP-6357 and then isolating the isochroman compound from the fermentation broth. The present invention also relates to a pharmaceutical composition comprising the isochroman compound.